Today: 19 November 2025
Subscribe
Browse Category

Biotech News 7 October 2025 - 18 October 2025

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

Key Facts – October 18, 2025 Stock Soars on Breakthrough News and Funding Boost ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7% on Friday (Oct 17) alone, finishing at $6.45 marketbeat.com, after trading around the mid-$5 range earlier in the week. In fact, as of early Friday, ATAI was already up about 8% for the week on anticipation of the announcements nasdaq.com. The strong finish came as investors digested multiple catalysts: a coveted FDA designation for a key drug, a fresh capital raise, and bullish commentary from analysts. Notably, after-hours
18 October 2025
 ·  ·  ·  ·  · 
Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

FDA Voucher Ignites IRON Stock Rally Disc Medicine’s stock price (NASDAQ: IRON) spiked dramatically in mid-October 2025 after news of the FDA voucher, vaulting from the mid-$70s to the low-$90s in a single day gurufocus.com. On Friday (Oct. 17), IRON opened around $85 and surged to an intraday high of $92.50 before closing at $93.00, marking a ~25% jump on the day stockanalysis.com. This leap capped a steady uptrend over the past month – the shares were trading near $60 in early September and gradually climbed into the $70s as anticipation built around bitopertin’s NDA filing and review stockanalysis.com stockanalysis.com.
17 October 2025
 ·  ·  ·  · 
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market open tipranks.com. The stock, which had closed at just $0.47 the prior day, briefly hit approximately $1.37 per share – nearly a 3× gain in value google.com. By midday, shares were still trading around the $1.30 level, up almost +180% on the day. This stunning one-day move snapped RANI out of penny-stock territory and back above the Nasdaq’s $1 minimum
17 October 2025
 ·  ·  ·  ·  · 
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30% after-hours to ~$0.20 ts2.tech. This stunning one-day move – without any company-specific catalyst – was accompanied by an enormous volume of 705+ million shares traded (versus ~60 million on an average day) ts2.tech. Market observers noted Adaptimmune as one of
16 October 2025
 ·  ·  ·  ·  ·  · 
Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

Stock Performance Over the past few trading days, NDRA moved sharply higher. It closed $6.48 on Oct 10, 2025 stockinvest.us, up modestly from ~$5.75 a week earlier. On Oct. 13, after the morning press release, the stock leapt 33.1% to ~$8.625 by mid-day markets.financialcontent.com. This surge came before any actual crypto investment; it reflects investor excitement (and speculation) about ENDRA’s new Digital Asset Treasury plan. The stock had been drifting up in September/October, but the rally was supercharged by the news. Keep in mind NDRA is a microcap: only ~0.75 million shares outstanding and a market cap under $5 million finviz.com, so
13 October 2025
 ·  ·  ·  ·  · 
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied (+5% in Europe) after Pfizer announced a U.S. drug-pricing deal reuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals (50-day MA ≈ $214; 200-day
11 October 2025
 ·  ·  ·  ·  · 
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platform protagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership &
11 October 2025
 ·  ·  ·  · 
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery news.bms.com fiercebiotech.com. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ news.bms.com orbitaltx.com. This approach could
10 October 2025
 ·  ·  ·  ·  · 
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015 renaissancecapital.com. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept 2025 ahead of its Nasdaq listing stockanalysis.com. Turn’s mission is to “turn the tides” in medicine by developing technologies that heal, not just manage, challenging traditional treatments benzinga.com. CEO Bradley Burnam (the founder) leads a lean operation “built on a shoestring, with an absolute disdain for waste,” as he emphasized during the Nasdaq bell-ringing ceremony benzinga.com. Burnam and his team bring a “patient-first” approach and a frugal business model to drug development, aiming
9 October 2025
 ·  ·  ·  ·  · 
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase II completed (42% response rate) stocktitan.net; FDA Breakthroughdesignation in 2025 stocktitan.net; BLA filing planned for 2025. Sold to US WorldMeds (2025) adaptimmune.com Uzatresegene (uza-cel, next-gen TCR) Solid tumors (MAGE-A4 TCR, partnered with Galapagos) Preclinical/IND-enabling stage; partnership deal $665M signed 2024 fiercebiotech.com. Sold to US WorldMeds (2025) adaptimmune.com PRAME-targeted TCR Multiple cancers (PRAME antigen) Preclinical (IND-enabling on hold to cut costs) biospace.com. Retained by Adaptimmune adaptimmune.com CD70-targeted TCR Hematologic malignancies
8 October 2025
 ·  ·  ·  ·  · 
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting the stock to about $14.02 by mid-day marketbeat.com marketbeat.com. This rally builds on a strong upward trend in recent months – the stock traded below $8 in spring 2025, so it has nearly doubled since then. Trading volume actually dipped on the spike (about 331,000 shares vs. a 2.6 million average), indicating the price jolt came on limited activity marketbeat.com
7 October 2025
 ·  ·  ·  ·  · 
Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

GLTO’s 632% Stock Spike: What Just Happened? Galecto’s stock made headlines on October 7, 2025 by soaring roughly six-fold in value within hours. In pre-market trading that morning, GLTO was up about 632% at one point stocktwits.com stocktwits.com. Shares that had closed around $3–4 the prior day suddenly traded in the high teens, hitting over two-year highs stocktwits.com stocktwits.com. Crucially, no new announcement or fundamental development explained this explosion – “there are no new press releases or SEC filings” to account for the surge, one report noted tipranks.com. In other words, the rally appears to have been purely market-driven, likely triggered by momentum buyers or algorithmic traders seizing on
7 October 2025
 ·  ·  ·  ·  · 
1 2 3 4 5 6 7
Go toTop